echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Rongchang Biological Vidicuzumab was identified as a breakthrough therapy for its indications

    Rongchang Biological Vidicuzumab was identified as a breakthrough therapy for its indications

    • Last Update: 2021-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 29, the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) showed that China’s first original antibody-conjugated drug (ADC) new drug, vedixituzumab ("injectable Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent") was officially included in the breakthrough treatment category, and the indications are HER2-positive advanced breast cancer patients with liver metastases who have been treated with trastuzumab and taxanes in the past


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.